News
Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...
When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback